Obesity drugs, 'Wegovy vs Mounjaro' after expanded approval
By Hwang, Byung-woo
24.08.03 05:57:19
가나다라
0
Mounjaro wins another approval, a year after its approval for type 2 diabetes
Wegovy wins approval based on the SELECT study showing a reduced risk of cardiovascular diseases
Wegovy and Mounjaro, regarded as next-generation treatments for obesity, have expanded indications. As a result, intense competition in the market is expected.
▲(From the left) Product photos of Mounjaro and Wegovy.
On July 1st, Eli Lily's Mounjaro (ingredient: tirzepatide) received approval as an adjunct for chronic weight management, a year after it received approval as a type 2 diabetes treatment in June last year.
The expansion of Mounjaro's indication suggests that it will likely shift the market for obesity drugs in South Korea.
Novo Nordisk's Wegovy (ingredient: semaglutide) and Mounjaro (U.S. product name: Zepbound) are currently dominating the global market.
Wegovy generated global sales of US$4.5 billio
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)